{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:14:22Z","timestamp":1761743662698},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T00:00:00Z","timestamp":1347926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00406-012-0362-3","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T06:47:15Z","timestamp":1347864435000},"page":"71-77","source":"Crossref","is-referenced-by-count":25,"title":["Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer\u2019s disease and other neurodegenerative dementias"],"prefix":"10.1007","volume":"262","author":[{"given":"J.","family":"Genius","sequence":"first","affiliation":[]},{"given":"H.","family":"Klafki","sequence":"additional","affiliation":[]},{"given":"J.","family":"Benninghoff","sequence":"additional","affiliation":[]},{"given":"H.","family":"Esselmann","sequence":"additional","affiliation":[]},{"given":"J.","family":"Wiltfang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,9,18]]},"reference":[{"issue":"3","key":"362_CR1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):270\u2013279","journal-title":"Alzheimers Dement"},{"issue":"5","key":"362_CR2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","volume":"159","author":"GE Alexander","year":"2002","unstructured":"Alexander GE, Chen K et al (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer\u2019s disease treatment studies. Am J Psychiatr 159(5):738\u2013745","journal-title":"Am J Psychiatr"},{"issue":"11","key":"362_CR3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/archneur.62.11.1728","volume":"62","author":"D Anchisi","year":"2005","unstructured":"Anchisi D, Borroni B et al (2005) Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62(11):1728\u20131733","journal-title":"Arch Neurol"},{"issue":"1","key":"362_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/17520363.1.1.59","volume":"1","author":"U Andreasson","year":"2007","unstructured":"Andreasson U, Portelius E et al (2007) Aspects of beta-amyloid as a biomarker for Alzheimer\u2019s disease. Biomarkers Med 1(1):59\u201378","journal-title":"Biomarkers Med"},{"issue":"1","key":"362_CR5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/exnr.2000.7501","volume":"166","author":"H Arai","year":"2000","unstructured":"Arai H, Ishiguro K et al (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166(1):201\u2013203","journal-title":"Exp Neurol"},{"issue":"10","key":"362_CR6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol 2(10):605\u2013613","journal-title":"Lancet Neurol"},{"issue":"1\u20133","key":"362_CR7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MN:24:1-3:087","volume":"24","author":"K Blennow","year":"2001","unstructured":"Blennow K, Vanmechelen E et al (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer\u2019s disease. Mol Neurobiol 24(1\u20133):87\u201397","journal-title":"Mol Neurobiol"},{"issue":"1","key":"362_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Buee","year":"2000","unstructured":"Buee L, Bussiere T et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33(1):95\u2013130","journal-title":"Brain Res Brain Res Rev"},{"issue":"Pt 11","key":"362_CR9","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain J Neurol 129(Pt 11):3035\u20133041","journal-title":"Brain J Neurol"},{"issue":"4","key":"362_CR10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Teipel SJ et al (2002) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59(4):627\u2013629","journal-title":"Neurology"},{"issue":"8","key":"362_CR11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1212\/01.WNL.0000055847.17752.E6","volume":"60","author":"G Chetelat","year":"2003","unstructured":"Chetelat G, Desgranges B et al (2003) Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer\u2019s disease? Neurology 60(8):1374\u20131377","journal-title":"Neurology"},{"issue":"18","key":"362_CR12","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1001\/archinte.163.18.2219","volume":"163","author":"AM Clarfield","year":"2003","unstructured":"Clarfield AM (2003) The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 163(18):2219\u20132229","journal-title":"Arch Intern Med"},{"issue":"3","key":"362_CR13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512\u2013519","journal-title":"Ann Neurol"},{"issue":"8\u20139","key":"362_CR14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med 1(8\u20139):371\u2013380","journal-title":"EMBO Mol Med"},{"issue":"16","key":"362_CR15","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16):1349\u20131356","journal-title":"JAMA"},{"issue":"9503","key":"362_CR16","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503):2112\u20132117","journal-title":"Lancet"},{"issue":"2","key":"362_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/157488408784293723","volume":"3","author":"SV Frankfort","year":"2008","unstructured":"Frankfort SV, Tulner LR et al (2008) Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 3(2):123\u2013131","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"362_CR18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31887\/DCNS.2009.11.2\/hhampel","volume":"11","author":"H Hampel","year":"2009","unstructured":"Hampel H, Broich K et al (2009) Biological markers for early detection and pharmacological treatment of Alzheimer\u2019s disease. Dialogues Clin Neurosci 11(2):141\u2013157","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"362_CR19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatr 61(1):95\u2013102","journal-title":"Arch Gen Psychiatr"},{"issue":"1","key":"362_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","volume":"4","author":"H Hampel","year":"2008","unstructured":"Hampel H, Burger K et al (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer\u2019s disease. Alzheimers Dement 4(1):38\u201348","journal-title":"Alzheimers Dement"},{"issue":"7","key":"362_CR21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, Frank R et al (2010) Biomarkers for Alzheimer\u2019s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9(7):560\u2013574","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"362_CR22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pneurobio.2010.11.005","volume":"95","author":"H Hampel","year":"2011","unstructured":"Hampel H, Wilcock G et al (2011) Biomarkers for Alzheimer\u2019s disease therapeutic trials. Prog Neurobiol 95(4):579\u2013593","journal-title":"Prog Neurobiol"},{"issue":"3","key":"362_CR23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H et al (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228\u2013234","journal-title":"Lancet Neurol"},{"issue":"5580","key":"362_CR24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297(5580):353\u2013356","journal-title":"Science"},{"issue":"10","key":"362_CR25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet 41(10):1088\u20131093","journal-title":"Nat Genet"},{"issue":"9","key":"362_CR26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archneur.65.9.1211","volume":"65","author":"V Haroutunian","year":"2008","unstructured":"Haroutunian V, Schnaider-Beeri M et al (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65(9):1211\u20131217","journal-title":"Arch Neurol"},{"issue":"5","key":"362_CR27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D et al (2011) Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet 43(5):429\u2013435","journal-title":"Nat Genet"},{"issue":"3","key":"362_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0304-3940(02)00047-2","volume":"320","author":"YY Hu","year":"2002","unstructured":"Hu YY, He SS et al (2002) Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 320(3):156\u2013160","journal-title":"Neurosci Lett"},{"issue":"3","key":"362_CR29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, Albert MS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):257\u2013262","journal-title":"Alzheimers Dement"},{"issue":"7409","key":"362_CR30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK et al (2012) A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature 488(7409):96\u201399","journal-title":"Nature"},{"issue":"3","key":"362_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM et al (2009) The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron 63(3):287\u2013303","journal-title":"Neuron"},{"issue":"3","key":"362_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H et al (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol 55(3):306\u2013319","journal-title":"Ann Neurol"},{"issue":"5","key":"362_CR33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000210388","volume":"27","author":"J Kornhuber","year":"2009","unstructured":"Kornhuber J, Schmidtke K et al (2009) Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord 27(5):404\u2013417","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"10","key":"362_CR34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet 41(10):1094\u20131099","journal-title":"Nat Genet"},{"issue":"7","key":"362_CR35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","volume":"69","author":"G Li","year":"2007","unstructured":"Li G, Sokal I et al (2007) CSF tau\/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69(7):631\u2013639","journal-title":"Neurology"},{"issue":"11","key":"362_CR36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0962-8924(98)01368-3","volume":"8","author":"EM Mandelkow","year":"1998","unstructured":"Mandelkow EM, Mandelkow E (1998) Tau in Alzheimer\u2019s disease. Trends Cell Biol 8(11):425\u2013427","journal-title":"Trends Cell Biol"},{"issue":"7265","key":"362_CR37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio TA, Collins FS et al (2009) Finding the missing heritability of complex diseases. Nature 461(7265):747\u2013753","journal-title":"Nature"},{"issue":"4","key":"362_CR38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U et al (2011) The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7(4):386\u2013395","journal-title":"Alzheimers Dement"},{"issue":"4","key":"362_CR39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4):385\u2013393","journal-title":"JAMA"},{"issue":"8","key":"362_CR40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1056\/NEJM199802193380804","volume":"338","author":"R Mayeux","year":"1998","unstructured":"Mayeux R, Saunders AM et al (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Disease Centers Consortium on Apolipoprotein E and Alzheimer\u2019s Disease. N Engl J Med 338(8):506\u2013511","journal-title":"N Engl J Med"},{"issue":"7","key":"362_CR41","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D et al (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"3","key":"362_CR42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):263\u2013269","journal-title":"Alzheimers Dement"},{"issue":"19","key":"362_CR43","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1212\/WNL.0b013e318236f0cf","volume":"77","author":"LE Middleton","year":"2011","unstructured":"Middleton LE, Grinberg LT et al (2011) Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology 77(19):1737\u20131744","journal-title":"Neurology"},{"issue":"9","key":"362_CR44","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/jnnp.2008.167791","volume":"80","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer\u2019s disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80(9):966\u2013975","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"362_CR45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J et al (2009) Conversion of amyloid positive and negative MCI to AD over 3\u00a0years: an 11C-PIB PET study. Neurology 73(10):754\u2013760","journal-title":"Neurology"},{"issue":"2","key":"362_CR46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1212\/WNL.58.2.192","volume":"58","author":"M Otto","year":"2002","unstructured":"Otto M, Wiltfang J et al (2002) Tau protein and 14\u20133\u20133 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58(2):192\u2013197","journal-title":"Neurology"},{"issue":"1","key":"362_CR47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.RES.44.1.127","volume":"44","author":"M Reivich","year":"1979","unstructured":"Reivich M, Kuhl D et al (1979) The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44(1):127\u2013137","journal-title":"Circ Res"},{"key":"362_CR48","volume-title":"The Alzheimer myth and biomarker research in Dementia","author":"E Richard","year":"2012","unstructured":"Richard E, Schmand B et al (2012) The Alzheimer myth and biomarker research in Dementia. J Alzheimers Dis, JAD"},{"issue":"4","key":"362_CR49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/156720509788929273","volume":"6","author":"SL Risacher","year":"2009","unstructured":"Risacher SL, Saykin AJ et al (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6(4):347\u2013361","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"362_CR50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.410380105","volume":"38","author":"AD Roses","year":"1995","unstructured":"Roses AD (1995) Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer\u2019s disease. Ann Neurol 38(1):6\u201314","journal-title":"Ann Neurol"},{"issue":"2","key":"362_CR51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U et al (2008) Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7(2):129\u2013135","journal-title":"Lancet Neurol"},{"issue":"9020","key":"362_CR52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0140-6736(96)01251-2","volume":"348","author":"AM Saunders","year":"1996","unstructured":"Saunders AM, Hulette O et al (1996) Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer\u2019s disease. Lancet 348(9020):90\u201393","journal-title":"Lancet"},{"issue":"22","key":"362_CR53","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","volume":"360","author":"GM Savva","year":"2009","unstructured":"Savva GM, Wharton SB et al (2009) Age, neuropathology, and dementia. N Engl J Med 360(22):2302\u20132309","journal-title":"N Engl J Med"},{"issue":"9","key":"362_CR54","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archneurol.2011.189","volume":"68","author":"C Schmidt","year":"2011","unstructured":"Schmidt C, Wolff M et al (2011) Rapidly progressive Alzheimer disease. Arch Neurol 68(9):1124\u20131130","journal-title":"Arch Neurol"},{"issue":"1","key":"362_CR55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","volume":"78","author":"NS Schoonenboom","year":"2012","unstructured":"Schoonenboom NS, Reesink FE et al (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78(1):47\u201354","journal-title":"Neurology"},{"issue":"20","key":"362_CR56","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Seppala","year":"2012","unstructured":"Seppala TT, Nerg O et al (2012) CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78(20):1568\u20131575","journal-title":"Neurology"},{"issue":"4","key":"362_CR57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol 65(4):403\u2013413","journal-title":"Ann Neurol"},{"issue":"2","key":"362_CR58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-510X(98)00122-1","volume":"158","author":"M Shoji","year":"1998","unstructured":"Shoji M, Matsubara E et al (1998) Combination assay of CSF tau, A beta 1\u201340 and A beta 1\u201342(43) as a biochemical marker of Alzheimer\u2019s disease. J Neurol Sci 158(2):134\u2013140","journal-title":"J Neurol Sci"},{"issue":"5","key":"362_CR59","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archneurol.2009.55","volume":"66","author":"BJ Snider","year":"2009","unstructured":"Snider BJ, Fagan AM et al (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66(5):638\u2013645","journal-title":"Arch Neurol"},{"issue":"3","key":"362_CR60","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS et al (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):280\u2013292","journal-title":"Alzheimers Dement"},{"issue":"4","key":"362_CR61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K et al (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4):652\u2013656","journal-title":"Neurology"},{"issue":"16","key":"362_CR62","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland T, Linker G et al (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289(16):2094\u20132103","journal-title":"JAMA"},{"issue":"Suppl 1","key":"362_CR63","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1007\/s00259-007-0703-z","volume":"35","author":"SJ Teipel","year":"2008","unstructured":"Teipel SJ, Meindl T et al (2008) Novel MRI techniques in the assessment of dementia. Euro J Nucl Med Mol Imaging 35(Suppl 1):S58\u2013S69","journal-title":"Euro J Nucl Med Mol Imaging"},{"issue":"12","key":"362_CR64","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U et al (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791\u20131800","journal-title":"Neurology"},{"issue":"4","key":"362_CR65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/WNL.0b013e3181af79e5","volume":"73","author":"P Vemuri","year":"2009","unstructured":"Vemuri P, Wiste HJ et al (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73(4):287\u2013293","journal-title":"Neurology"},{"issue":"7","key":"362_CR66","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser PJ, Verhey F et al (2009) Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8(7):619\u2013627","journal-title":"Lancet Neurol"},{"issue":"2","key":"362_CR67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00702-008-0177-6","volume":"116","author":"V Welge","year":"2009","unstructured":"Welge V, Fiege O et al (2009) Combined CSF tau, p-tau181 and amyloid-beta 38\/40\/42 for diagnosing Alzheimer\u2019s disease. J Neural Trans 116(2):203\u2013212","journal-title":"J Neural Trans"},{"issue":"6","key":"362_CR68","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1471-4159.1999.0732485.x","volume":"73","author":"J Wiltfang","year":"1999","unstructured":"Wiltfang J, Otto M et al (1999) Isoform pattern of 14\u20133\u20133 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem 73(6):2485\u20132490","journal-title":"J Neurochem"},{"issue":"1","key":"362_CR69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.410430109","volume":"43","author":"I Zerr","year":"1998","unstructured":"Zerr I, Bodemer M et al (1998) Detection of 14\u20133\u20133 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43(1):32\u201340","journal-title":"Ann Neurol"},{"issue":"5","key":"362_CR70","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/erm.10.48","volume":"10","author":"T Zetzsche","year":"2010","unstructured":"Zetzsche T, Rujescu D et al (2010) Advances and perspectives from genetic research: development of biological markers in Alzheimer\u2019s disease. Expert Rev Mol Diagn 10(5):667\u2013690","journal-title":"Expert Rev Mol Diagn"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-012-0362-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-012-0362-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-012-0362-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T07:11:47Z","timestamp":1643440307000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-012-0362-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,18]]},"references-count":70,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1007\/s00406-012-0362-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,18]]}}}